VS-101
Phase 1/2a- Indications
- Glaucoma
Company intelligence / Profile preview
Micromedic Technologies developed a portfolio of innovative molecular diagnostic solutions focused primarily on early detection and personalized management of various cancers. The company’s pipeline included tests targeting colorectal, breast, cervical, bladder, and lung cancers. Its approach spanned from screening/risk identification to disease monitoring. Some products reached commercialization while others remained under development. The company operated through strategic collaborations with scientific institutes worldwide as well as internal R&D efforts before being renamed/acquired by Nextage Therapeutics Ltd.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Micromedic Technologies.